Suppr超能文献

特发性肺动脉高压患者血栓形成和纤维蛋白溶解的标志物及其与炎症和内皮激活的关系。

Markers of thrombogenesis and fibrinolysis and their relation to inflammation and endothelial activation in patients with idiopathic pulmonary arterial hypertension.

作者信息

Kopeć Grzegorz, Moertl Deddo, Steiner Sabine, Stępień Ewa, Mikołajczyk Tomasz, Podolec Jakub, Waligóra Marcin, Stępniewski Jakub, Tomkiewicz-Pająk Lidia, Guzik Tomasz, Podolec Piotr

机构信息

Department of Cardiac and Vascular Diseases of the John Paul II Hospital in Krakow and the Jagiellonian University Collegium Medicum, Krakow, Poland.

出版信息

PLoS One. 2013 Dec 2;8(12):e82628. doi: 10.1371/journal.pone.0082628. eCollection 2013.

Abstract

BACKGROUND

Chronic anticoagulation is a standard of care in idiopathic pulmonary arterial hypertension (IPAH). However, hemostatic abnormalities in this disease remain poorly understood. Therefore, we aimed to study markers of thrombogenesis and fibrinolysis in patients with IPAH.

METHODS

We studied 27 consecutive patients (67% female) with IPAH aged 50.0 years (IQR: 41.0-65.0) and 16 controls without pulmonary hypertension. Prothrombin fragment 1+2 (F1+2) and thrombin-antithrombin (TAT) complexes were measured to assess thrombogenesis; tissue-type plasminogen activator (tPA) antigen and plasmin-anti-plasmin complex to characterize activation of fibrinolysis; plasminogen activator inhibitor 1 (PAI-1) to measure inhibition of fibrinolysis; and endothelin-1 (ET-1) and interleukin-6 (IL-6) to assess endothelial activation and systemic inflammation, respectively. In addition, in treatment-naive IPAH patients these markers were assessed after 3 months of PAH-specific therapies.

RESULTS

TPA (10.1[6.8-15.8] vs 5.2[3.3-7.3] ng/ml, p<0.001), plasmin-anti-plasmin (91.5[60.3-94.2] vs 55.8[51.1-64.9] ng/ml, p<0.001), IL-6 (4.9[2.5-7.9] vs 2.1[1.3-3.8] pg/ml, p=0.001) and ET-1 (3.7 [3.3-4.5] vs 3.4[3.1-3.5], p= 0.03) were higher in patients with IPAH than in controls. In IPAH patients plasmin-anti-plasmin and tPA correlated positively with IL-6 (r=0.39, p=0.04 and r=0.63, p<0.001, respectively) and ET-1 (r=0.55, p=0.003 and r=0.59, p=0.001, respectively). No correlation was found between tPA or plasmin-anti-plasmin and markers of thrombogenesis. Plasmin-anti-plasmin decreased after 3 months of PAH specific therapy while the other markers remained unchanged.

CONCLUSIONS

In the present study we showed that markers of fibrynolysis were elevated in patients with IPAH however we did not find a clear evidence for increased thrombogenesis in this group of patients. Fibrinolysis, inflammation, and endothelial activation were closely interrelated in IPAH.

摘要

背景

长期抗凝是特发性肺动脉高压(IPAH)的标准治疗方法。然而,该疾病中的止血异常仍未得到充分理解。因此,我们旨在研究IPAH患者的血栓形成和纤维蛋白溶解标志物。

方法

我们研究了27例连续的IPAH患者(67%为女性),年龄50.0岁(四分位间距:41.0 - 65.0),以及16例无肺动脉高压的对照者。测量凝血酶原片段1 + 2(F1 + 2)和凝血酶 - 抗凝血酶(TAT)复合物以评估血栓形成;测量组织型纤溶酶原激活物(tPA)抗原和纤溶酶 - 抗纤溶酶复合物以表征纤维蛋白溶解的激活;测量纤溶酶原激活物抑制剂1(PAI - 1)以测定纤维蛋白溶解的抑制;测量内皮素 - 1(ET - 1)和白细胞介素 - 6(IL - 6)分别评估内皮激活和全身炎症。此外,在未接受过治疗的IPAH患者中,在进行3个月的PAH特异性治疗后评估这些标志物。

结果

IPAH患者的tPA(10.1[6.8 - 15.8]对5.2[3.3 - 7.3] ng/ml,p < 0.001)、纤溶酶 - 抗纤溶酶(91.5[60.3 - 94.2]对55.8[51.1 - 64.9] ng/ml,p < 0.001)、IL - 6(4.9[2.5 - 7.9]对2.1[1.3 - 3.8] pg/ml,p = 0.001)和ET - 1(3.7 [3.3 - 4.5]对3.4[3.1 - 3.5],p = 0.03)高于对照组。在IPAH患者中,纤溶酶 - 抗纤溶酶和tPA分别与IL - 6(r = 0.39,p = 0.04和r = 0.63,p < 0.001)以及ET - 1(r = 0.55,p = 0.003和r = 0.59,p = 0.001)呈正相关。未发现tPA或纤溶酶 - 抗纤溶酶与血栓形成标志物之间存在相关性。PAH特异性治疗3个月后,纤溶酶 - 抗纤溶酶降低,而其他标志物保持不变。

结论

在本研究中,我们表明IPAH患者的纤维蛋白溶解标志物升高,但在该组患者中未发现血栓形成增加的确切证据。在IPAH中,纤维蛋白溶解、炎症和内皮激活密切相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ceca/3847115/fbb48a9db541/pone.0082628.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验